Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells attack the central nervous system, causing irreversible damage. Current ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Grace Miller was a 24-year-old law school student when she was diagnosed with multiple sclerosis ...

Multiple sclerosis (MS) is a chronic, often debilitating autoimmune disease that affects the central nervous system (CNS).

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Autoimmune diseases such as multiple sclerosis arise when the immune system turns against the body itself. Yet for most of them, it remains unclear why this process begins. Researchers have now ...

Please provide your email address to receive an email when new articles are posted on . WEST PALM BEACH, Fla. — More than a century of scientific research has shed light on the neuroimmune interaction ...

Now, by analyzing thousands of proteins found in the blood, scientists at UC San Francisco have created the clearest picture yet of when the disease attacks the myelin sheath that covers the nerve ...

The results of preclinical research headed by a team at Karolinska Institutet have indicated how T cells that play a role in the immune system’s reaction to the common Epstein-Barr virus (EBV) can ...

A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first ...